Navigation Links
Agendia Signs Contract with Blue Shield of California
Date:1/5/2012

gendia's Symphony™ suite of breast cancer products is based on the analysis of hundreds of genes in a patient's breast and provides unprecedented biological insight to address complex treatment decisions. Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint­­, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, a therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo or hormonal therapy, and which patients do not require these treatments and can instead be treated with other less arduous and costly methods.

In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development based on its world-class genomic platform. The company also collaborates with pharmaceutical companies to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.

Agendia was founded in 2003 as a spin-off of the Netherlands Cancer Institute and is based in Irvine, California, United States, and Amsterdam, the Netherlands. For more information, please visit www.agendia.com.

For further information, please contact:

Ricochet Public Relations
Todd Aydelotte
Tel: +1 212 679 3300
E-mail: todd@ricochetpr.com


'/>"/>
SOURCE Agendia
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Agendia to Present Five Abstracts at 2011 San Antonio Breast Cancer Symposium
2. EORTC, BIG, and Agendia Announce Completion of Patient Recruitment for International MINDACT Study
3. Agendia Successfully Completes Bi-Annual FDA Inspection
4. Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting
5. Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists
6. Medicare Administrator Establishes Reimbursement Coding Policy for Agendias Breast Cancer Recurrence Test MammaPrint(R)
7. Agendia Raises US $23 Million in Series E Financing
8. Agendia Supports Genentechs Citizens Petition Urging FDA to Hold In-Vitro Diagnostic Tests to One Set of Scientific and Regulatory Standards
9. Agendia Opens CLIA-Registered U.S. Genomics Laboratory
10. Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting
11. Agendia to Present at BioCenturys Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... October 01, 2014 TeselaGen Biotechnology ... Science Foundation to expand their bioCAD/CAM software suite, which ... modify DNA. The Small Business Innovation Research Phase II ... technology under exclusive license from the Lawrence Berkeley National ... Institute , an LBNL laboratory that develops alternative fuel ...
(Date:10/1/2014)... 1, 2014 Industry leaders ... to engage around the theme, ,Commercial Opportunities in the ...   Elsevier , a world-leading provider ... will host a gathering of some of the industry,s ... impacting healthcare today and in the future. The ...
(Date:9/30/2014)... news release is available in German . ... the Technische Universitt Mnchen (TUM) have demonstrated a new ... experiments show that future computer chips could be based ... As the main enabling technology of the semiconductor industry ... limits, the TUM researchers and collaborators at the University ...
(Date:9/30/2014)... 2014 Report Details Biosimilar drugs ... revenues Do you want to find sales potentials ... predictions for those biological drugs from 2014, helping ... financial data, R&D trends, opportunities and selling prospects. ... to 2024 at overall world market, therapeutic class, ...
Breaking Biology Technology:TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5
... ATLANTA, Georgia , March 14, 2010 ... type 2 diabetes patients with,atherogenic dyslipidemia, the common combination of ... low levels of high-density,lipoprotein cholesterol (HDL-C, 34 mg/dL or 0.88 ... Only 20 of these patients need,to be treated for 5 ...
... ... is taking strides to expand their Product and Material Testing Division by promoting Mark Francis ... Minneapolis, ... and material testing, is taking strides to expand their Product and Material Testing Division by ...
... FRANCISCO , March 12 Medivation, Inc. (Nasdaq: MDVN ) today announced that it will ... a general business update on March 15, 2010 , at 4:30 p.m. Eastern Time . A ... after markets close on March 15, 2010 . , ... ...
Cached Biology Technology:ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 2ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 3ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 4ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 5ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 6ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 7ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 8ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 9DDL Expands the Product & Material Testing Division 2DDL Expands the Product & Material Testing Division 3Medivation Announces Fourth Quarter and Year-End 2009 Financial Results Teleconference and Webcast On March 15, 2010 2Medivation Announces Fourth Quarter and Year-End 2009 Financial Results Teleconference and Webcast On March 15, 2010 3
(Date:10/2/2014)... The global genomics market was valued at $11.11 billion ... CAGR of over 12.0% from 2013 to 2018. The ... applications, and advancements in existing technologies plays an important ... this market. Next Generation Sequencing (NGS) in personalized medicine ... area for the global genomics market. This new technology ...
(Date:10/1/2014)... Reserve University researchers hope to take a healthy salad ... aggressive form of breast cancer in leafy greens. , ... the vaccine either by eating the salad or making ... assistant professor of biomedical engineering at Case Western Reserve ... The Susan G. Komen breast cancer organization is funding ...
(Date:10/1/2014)... Novel detection technology is ... The life science field has seen ... years. Some are shooting stars and others become ... detection technology that has raised much enthusiasm among ... is becoming commercially available. With their unique advantages, ...
Breaking Biology News(10 mins):Genomics Market by Products - [Instruments (NGS platform, Microarray, RT-PCR), Consumables (Genechips, Reagents for DNA Extraction & Purification, Sequencing)], Services (Sequencing & Microarray Services, and Software) - Global Forecast to 2018 2Scientists wield plant viruses against deadly human disease 2Scientists wield plant viruses against deadly human disease 3First-of-a-kind Solution for Utilizing Photon Upconversion 2
... The International Council for Science (ICSU), within ... major 10-year initiative which aims to effectively deliver ... This new international collaboration effort, the Earth System ... to respond to the most pressing societal and ...
... key regulator that controls the speed of development in the ... regulator, animals sped up their rate of development and reached ... A research team, led by molecular geneticist Kirst King-Jones, noticed ... The protein acted as a sentinel to either allow or ...
... inequality around the world, the Journal of Visualized ... through the HINARI initiative to developing countries in South ... in biological research, JoVE is the first and only ... publishes video articles demonstrating advanced experiments performed in laboratories ...
Cached Biology News:Research solutions for sustainability in a rapidly changing world 2JoVE grants developing countries access to experimental videos 2
... Rabbit polyclonal to Taura ... Abpromise for all tested ... Synthetic peptide: VTNSEGSTIL MNDIPITNQN ... ATEFNQ, corresponding to N terminal ...
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
... Anti-acetyl-Histone H3 (Lys 4) ... the sequence ...RT[ Ac K]Q... in which ... 4 of human histone H3 ... Molecular Weight: Mr ~17kDa ...
Blank Calibration Particles, 3.0-3.4 mu m 5 ml...
Biology Products: